Liposarcoma clinical trials at UCSF
2 in progress, 1 open to eligible people
Liposarcoma is a type of cancer that affects fat cells. UCSF has a clinical trial for a new treatment called "CAB-AXL-ADC". This trial is open to adults and teenagers with sarcoma and focuses on the safety and effectiveness of the treatment. There is another trial in progress, but it is not accepting new participants at this time.
Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
open to eligible people ages 12 years and up
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in solid tumors
San Francisco, California and other locations
Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery
Sorry, in progress, not accepting new patients
This randomized phase II/III trial studies how well pazopanib, when combined with chemotherapy and radiation therapy or radiation therapy alone, work in the treatment of patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can eventually be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether these therapies can be safely combined and if they work better when given together in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.
Oakland, California and other locations
Our lead scientists for Liposarcoma research studies include Brian Schulte, MD.
Last updated: